Double-blind, Randomised, Parallel Group, Phase III Study
Patients will receive study drug every 3 weeks.
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
To Compare Efficacy
months
No
Investigational Site
Principal Investigator
Samsung Medical Center
Singapore: Health Sciences Authority
CT-P6/3.1
NCT01084876
June 2010
June 2013
Name | Location |
---|